Risks Of CVD For COX 2 Inhibitors Lower Than Previously Reported
Feb 27th 2008Drug InformationCardiovascular
In an article published in the March issue of the Journal of Cardiovascular Pharmacology and Therapeutics, researchers from Florida Atlantic University (FAU) assess the totality of evidence, including strengths and limitations of different types of evidence contributing to the debate about cardiovascular disease (CVD) risks of cyclooxygenase-2 (COX-2) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
